Designer drugs as a cause of homicide [1]

Addiction

Volumn 101, Issue 11, 2006, Pages 1666-1667

  Matsumoto, Toshihiko ^a   Okada, Takayuki ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNER DRUG; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CONSCIOUSNESS DISORDER; DRUG DEPENDENCE; DRUG LEGISLATION; FORENSIC SCIENCE; HOMICIDE; HUMAN; INTERNET; LETTER; MALE; PSYCHOSIS; SEROTONINERGIC SYSTEM;

ADULT; DESIGNER DRUGS; HALLUCINOGENS; HOMICIDE; HUMANS; MALE;

EID: 33749519615     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01573.x     Document Type: Letter

References (7)

1. Drug Enforcement Administration (DEA) Department of Justice. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. Fed Regist 2004; 69: 58950-3.
2. Ikeda A., Sekiguchi K., Fujita K., Yamadera H., Koga Y. 5-Methoxy-N,N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry 2005; 162: 815.
3. Meatherall R., Sharma P. Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 2003; 27: 313-17.
4. Wilson J. M., McGeorge F., Smolinske S., Meatherall R. A. Foxy intoxication. Forensic Sci Int 2005; 148: 31-6.
5. Shulgin A. T., Carter M. F. N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol 1980; 4: 363-9.
6. Goldberg R. J., Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics 1992; 33: 235-6.
7. Kojima H., Terao T., Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 1993; 150: 1897.